DNTH241220C15000
- 0.00
- 0.000.00%
Dianthus Therapeutics Newsroom
Powell Industries Reports Weak Sales, Joins Target, QuidelOrtho And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Oppenheimer Initiates Dianthus Therapeutics(DNTH.US) With Buy Rating, Announces Target Price $52
Dianthus Therapeutics Price Target Raised to $52.00/Share From $48.00 by Oppenheimer
Dianthus Therapeutics Is Maintained at Outperform by Oppenheimer
Express News | Raymond James Maintains Outperform on Dianthus Therapeutics, Raises Price Target to $56
LifeSci Capital Maintains Dianthus Therapeutics(DNTH.US) With Buy Rating, Maintains Target Price $45
Buy Recommendation for Dianthus Therapeutics: Strong Financial Position and Promising Drug Pipeline
Express News | Dianthus Therapeutics Q3 2024 GAAP EPS $(0.74) Misses $(0.58) Estimate, Sales $2.17M Beat $648.50K Estimate
Dianthus Therapeutics, Inc. (DNTH) Reports Q3 Loss, Tops Revenue Estimates
Dianthus Therapeutics | 10-Q: Q3 2024 Earnings Report
Express News | Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial Results
Press Release: Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial Results
Dianthus Therapeutics to Participate in Three Upcoming Healthcare Investor Conferences
Strength Seen in Dianthus Therapeutics, Inc. (DNTH): Can Its 5.7% Jump Turn Into More Strength?
Baird Maintains Dianthus Therapeutics(DNTH.US) With Buy Rating, Maintains Target Price $58
Guggenheim Initiates Dianthus Therapeutics(DNTH.US) With Buy Rating
Dianthus Started at Outperform by Oppenheimer on DNTH103 Opportunity
Oppenheimer Initiates Dianthus Therapeutics at Outperform With $48 Price Target
Express News | Dianthus Therapeutics Files for Resale of up to 23.7 Mln Shares of Common Stock by Selling Stockholders - SEC Filing
H.C. Wainwright Maintains Dianthus Therapeutics(DNTH.US) With Buy Rating, Maintains Target Price $40